Leigh Zawel - 07 Sep 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role: Chief Scientific Officer, Small Molecules
Signature: /s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol: CGEM
Transactions as of: 07 Sep 2021
Net transactions value: -$814,016
Form type: 4
Filing time: 08 Sep 2021, 16:15:19 UTC
Previous filing: 26 Aug 2021
Next filing: 21 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGEM	Common Stock	Sale	$814,016	-28,118	-30%	$28.95	65,406	07 Sep 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Scientific Officer, Small Molecules